Honolulu—An analysis of data from two phase 3 studies, presented at a poster session during the AAN meeting, found oral fingolimod more effective at preventing relapse in patients with multiple sclerosis (MS) than interferon beta-1a or...
Honolulu—An analysis of data from two phase 3 studies, presented at a poster session during the AAN meeting, found oral fingolimod more effective at preventing relapse in patients with multiple sclerosis (MS) than interferon beta-1a or...
Honolulu—An analysis of data...